BR112015025025A2 - composições terapêuticas e usos das mesmas - Google Patents

composições terapêuticas e usos das mesmas

Info

Publication number
BR112015025025A2
BR112015025025A2 BR112015025025A BR112015025025A BR112015025025A2 BR 112015025025 A2 BR112015025025 A2 BR 112015025025A2 BR 112015025025 A BR112015025025 A BR 112015025025A BR 112015025025 A BR112015025025 A BR 112015025025A BR 112015025025 A2 BR112015025025 A2 BR 112015025025A2
Authority
BR
Brazil
Prior art keywords
compositions
gastrointestinal
therapeutic compositions
gastrointestinal cancers
cyclodextrin
Prior art date
Application number
BR112015025025A
Other languages
English (en)
Inventor
Lazarova Lazarova Darina
Paul Kerry
Catchpole Owen
Original Assignee
Manuka Health New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manuka Health New Zealand Ltd filed Critical Manuka Health New Zealand Ltd
Publication of BR112015025025A2 publication Critical patent/BR112015025025A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Insects & Arthropods (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Molecular Biology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

abstract this invention provides pharmaceutical compositions, including anti-gastrointestinal cancer compositions, containing propolis and cyclodextrin. methods of using such compositions, in particular in the treatment or prevention of gastrointestinal cancers, and the resensitisation of gastrointestinal cancers to therapy are also provided. ________________________________________________ resumo "composições terapêuticas e usos das mesmas". a invenção fornece composições farmacêuticas, que incluem composições anticancerígenas gastrointestinais, que contêm própolis e ciclodextrina. também são fornecidos os métodos de uso de tais composições, em particular no tratamento ou prevenção de cânceres gastrointestinais, e na ressensibilização de cânceres gastrointestinais à terapia.
BR112015025025A 2013-04-05 2014-04-07 composições terapêuticas e usos das mesmas BR112015025025A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ60907413 2013-04-05
PCT/NZ2014/000060 WO2014163513A1 (en) 2013-04-05 2014-04-07 Therapeutic compositions and uses thereof

Publications (1)

Publication Number Publication Date
BR112015025025A2 true BR112015025025A2 (pt) 2017-07-18

Family

ID=51658696

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025025A BR112015025025A2 (pt) 2013-04-05 2014-04-07 composições terapêuticas e usos das mesmas

Country Status (13)

Country Link
US (2) US20160051594A1 (pt)
EP (1) EP2983681B1 (pt)
JP (1) JP6429859B2 (pt)
KR (1) KR20160021081A (pt)
CN (1) CN105307665B (pt)
AU (1) AU2014250139B2 (pt)
BR (1) BR112015025025A2 (pt)
CA (1) CA2908185A1 (pt)
EA (1) EA201591925A1 (pt)
HK (1) HK1220920A1 (pt)
SG (1) SG11201508167PA (pt)
TW (1) TW201532608A (pt)
WO (1) WO2014163513A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6444984B2 (ja) * 2013-04-05 2018-12-26 マヌカ ヘルス ニュージーランド リミテッド プロポリス抽出物を含む治療組成物およびその使用
CA2908185A1 (en) * 2013-04-05 2014-10-09 Manuka Health New Zealand Limited Therapeutic compositions and uses thereof
EP3169321B1 (en) * 2014-07-18 2020-07-15 Manuka Health New Zealand Limited Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health
AU2017237651A1 (en) * 2016-03-24 2018-11-01 Manuka Health New Zealand Limited Therapeutic compositions and uses thereof
ITUA20163755A1 (it) * 2016-05-24 2017-11-24 Aboca Spa Societa Agricola Composizioni a base di gemme di pioppo e loro usi
CN107194205B (zh) * 2017-05-31 2020-11-24 浙江大学 具有杀菌活性的jak2激酶抑制剂及其虚拟筛选方法
WO2019226469A1 (en) * 2018-05-19 2019-11-28 Fort Lewis College Chemical compositions for combating honey bee pests and pathogens
RU2697839C1 (ru) * 2018-11-14 2019-08-21 Александр Александрович Кролевец Способ получения нанокапсул сухого экстракта прополиса
JP7166965B2 (ja) * 2019-03-13 2022-11-08 株式会社ファンケル ｂＦＧＦ発現増強用組成物
TR201908777A2 (tr) * 2019-06-13 2019-07-22 Sbs Bilimsel Bio Coezuemler Sanayi Ve Ticaret A S Suda Çözünür ve Suda Çözünür Olmayan Özellikte Yüksek Antioksidan Kapasitesine Sahip Propolis Ürünleri ve Üretim Yöntemi
KR102470869B1 (ko) * 2020-12-18 2022-11-29 대한민국 프로테아좀 저해제 및 프로폴리스를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 및 이의 용도
CN117551222A (zh) * 2022-08-04 2024-02-13 中科中山药物创新研究院 大蒜素-环糊精包合物共晶的晶型及其制备方法和应用
CN116492324A (zh) * 2023-01-04 2023-07-28 河南科技大学第一附属医院 咖啡酸在预防和治疗结直肠癌中的应用、含咖啡酸的药物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JP3035834B2 (ja) * 1991-04-11 2000-04-24 株式会社林原生物化学研究所 プロポリス成分含有固状物とその製造方法並びに用途
US5561116A (en) 1991-04-11 1996-10-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Solid product containing propolis components, and preparation and uses thereof
US5922324A (en) 1995-01-31 1999-07-13 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Propolis extract with improved water-solubility
JP4135816B2 (ja) * 1995-11-24 2008-08-20 株式会社林原生物化学研究所 水溶性を向上させたプロポリス抽出物
CN1241577C (zh) * 2003-03-13 2006-02-15 吉林大学 环糊精衍生物的药物用途及其药物组合物
JP4950682B2 (ja) * 2007-01-30 2012-06-13 アピ株式会社 プロポリス抽出物
GR1007520B (el) * 2010-12-02 2012-02-02 Apivita - Καλλυντικα - Διαιτητικα - Φαρμακα Ανωνυμη Εμπορικη Και Βιοτεχνικη Εταιρεια, Ταυτοχρονη εκχυλιση και σχηματισμος συμπλοκων εγκλεισμου των δραστικων συστατικων της προπολης με υδροξυπροπυλο-β-κυκλοδεξτρινη
JP5938587B2 (ja) * 2011-01-31 2016-06-22 株式会社シクロケムバイオ 脂溶性物質を含む水溶液の製造方法
CA2908185A1 (en) * 2013-04-05 2014-10-09 Manuka Health New Zealand Limited Therapeutic compositions and uses thereof
JP6444984B2 (ja) 2013-04-05 2018-12-26 マヌカ ヘルス ニュージーランド リミテッド プロポリス抽出物を含む治療組成物およびその使用

Also Published As

Publication number Publication date
US10420804B2 (en) 2019-09-24
WO2014163513A1 (en) 2014-10-09
EP2983681B1 (en) 2020-07-15
SG11201508167PA (en) 2015-10-29
EP2983681A4 (en) 2017-01-04
JP2016516751A (ja) 2016-06-09
US20160051594A1 (en) 2016-02-25
JP6429859B2 (ja) 2018-11-28
HK1220920A1 (zh) 2017-05-19
AU2014250139B2 (en) 2019-09-12
CN105307665A (zh) 2016-02-03
AU2014250139A1 (en) 2015-11-12
US20170290865A1 (en) 2017-10-12
CN105307665B (zh) 2021-09-28
EP2983681A1 (en) 2016-02-17
EA201591925A1 (ru) 2016-02-29
KR20160021081A (ko) 2016-02-24
CA2908185A1 (en) 2014-10-09
TW201532608A (zh) 2015-09-01

Similar Documents

Publication Publication Date Title
BR112015025025A2 (pt) composições terapêuticas e usos das mesmas
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
PH12018502429A1 (en) Antibody molecules for cancer treatment
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
BR212016030926U2 (pt) conjugados de alvo e partículas e formulações dos mesmos
WO2016025635A3 (en) Combination therapy for treating cancer
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
NZ749218A (en) Androgen receptor modulator and uses thereof
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
MX2022015748A (es) Uso de una molecula anti-b7-h3 en combinacion con una molecula anti-pd-1 en la preparacion de formulaciones para el tratamiento de cancer.
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
MY187540A (en) Compounds active towards bromodomains
SA518400552B1 (ar) مركبات فوسفوراميدات
BR112018011228A2 (pt) tratamentos de combinação e seus usos e métodos
WO2015010078A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
SG10201902664RA (en) Combination therapy for treating cancer
WO2016043874A3 (en) Combination therapy for treating cancer
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
WO2017062615A3 (en) Combination therapy for the treatment of cancer
BR112018002530A2 (pt) combinações e usos e tratamentos destas
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]